Prasco, Takeda enter into agreement to market generic Colcrys

CINCINNATI and DEERFIELD, Ill. — Prasco Labs., Takeda Pharmacuetical Company Limited and Takeda's wholly owned subsidiary Takeda Pharmaceuticals U.S.A. on Tuesday announced that Prasco and TPUSA entered into a distribution and supply agreement for the rights to distribute colchicine tablets, USP, the authorized generic of Colcrys tablets. 

 

Because of the partnership, colchicine tablets will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys tablets, the companies said. 

 

"We are certainly pleased to partner with Takeda, an established leader in providing gout treatment options, to make an authorized generic of Colcrys widely available," said Jonathan Lapps, Prasco's SVP business development. 

 

The drug is used to treat acute glout flares in adults and the treatment of familial Mediterranean fever in adults and children age 4 years and older. Colchicine tablets will be marketed under the Prasco label and will be available in U.S. pharmacies beginning later this week, according to the company.